🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

18 recruiting trials

for Protein Kinase Inhibitors

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors NCT05643235NA1 site📍 New Hyde Park Northwell Health · Tests: Medtronic LINQ-2 Insertable Cardiac Monitor (ILR) Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study NCT06151730n/a1 site📍 Rochester Mayo Clinic · Tests: Non-Interventional Study A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors NCT04657068Phase 1, Phase 288 sites📍 Birmingham📍 Scottsdale📍 Little Rock Artios Pharma Ltd · Tests: ART0380, Gemcitabine, Irinotecan Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer NCT06190899Phase 1, Phase 213 sites📍 Detroit📍 Clermont-Ferrand📍 Marseille Celcuity Inc · Tests: Gedatolisib, Darolutamide DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations NCT06988475Phase 2, Phase 317 sites📍 Belfast📍 Birmingham📍 Bristol Cancer Research UK · Tests: Capmatinib DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers NCT05770037Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Alectinib A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT06973187Phase 3217 sites📍 Birmingham📍 Phoenix📍 Irvine BeOne Medicines · Tests: Tacabrutideg, Pirtobrutinib DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. NCT05770544Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Entrectinib Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations NCT07185997Phase 3139 sites📍 Fullerton📍 Los Angeles📍 Orange ArriVent BioPharma, Inc. · Tests: Firmonertinib, EGFR-TKI inhibitor based on investigator's choice International Chronic Myeloid Leukemia Pediatric Study NCT01281735n/a20 sites📍 North Adelaide📍 Vienna📍 Minsk Poitiers University Hospital Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors NCT06128148Phase 11 site📍 Guangzhou Guangzhou JOYO Pharma Co., Ltd · Tests: JYP0322 50 mg qd, JYP0322 100 mg qd, JYP0322 200 mg qd, JYP0322 100 mg bid, JYP0322 150 mg bid DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. NCT07440290Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Dabrafenib, Trametinib A Study of CSCJC3456 in Patients With Advanced Malignant Tumors NCT06717750Phase 12 sites📍 Beijing📍 Shenyang Changshan ConjuChem BioPharmaceutical Research and Developm… · Tests: CSCJC3456 tablet A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors NCT06846671Phase 3132 sites📍 Jonesboro📍 Los Angeles📍 San Diego BeOne Medicines · Tests: Tacabrutideg, Bendamustine, Idelalisib, Rituximab, Venetoclax A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) NCT07221500Phase 240 sites📍 Phoenix📍 Duarte📍 Los Angeles Nurix Therapeutics, Inc. · Tests: NX-5948 DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol NCT05722886Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Alectinib, Atezolizumab, Entrectinib, Trastuzumab in combination with pertuzumab, Vemurafenib in combination with cobim… Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) NCT06535568NA1 site📍 Milan Fondazione Ricerca e Innovazione Cardiovascolare ETS · Tests: Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT) Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma NCT05512481Phase 21 site📍 Beijing Peking University Cancer Hospital & Institute · Tests: Camrelizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy